Hospital
Lucy Webb Hayes National Training School for Deaconesses & Missionarie
Lucy Webb Hayes National Training School for Deaconesses & Missionarie was paid $19.10M by Medicaid between Jan 2018 and Nov 2024, across 173 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoLUCY WEBB HAYES NATIONAL TRAINING SCHOOL FOR DEACONESSES & MISSIONARIE
WASHINGTON, DC 20016
WASHINGTON, DC 20016
33aNPI1366492977assigned 05/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$19.10M
24GClaims343,502
24DCodes billed173
24AFirst – last monthJan 2018 – Nov 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DAVIS, RICHARD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,435 | $1.18M | |
| 2019 | 46,393 | $1.69M | |
| 2020 | 46,056 | $1.69M | |
| 2021 | 63,995 | $2.59M | |
| 2022 | 55,958 | $3.61M | |
| 2023 | 53,419 | $4.16M | |
| 2024incomplete | 44,246 | $4.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 17,243 | 15,195 | $4.22M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 13,615 | 11,914 | $3.18M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 10% | 9,155 | 7,818 | $1.94M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.2% | 4,514 | 4,109 | $1.37M |
| 70450 | Computed tomography, head or brain; without contrast material | 6.2% | 3,743 | 3,404 | $1.19M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.0% | 1,015 | 837 | $762K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.3% | 4,479 | 1,410 | $631K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.8% | 1,255 | 1,129 | $530K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.6% | 3,137 | 1,783 | $502K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.5% | 2,850 | 2,359 | $471K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.4% | 3,033 | 2,703 | $455K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.0% | 1,885 | 1,627 | $384K |
161 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.0% | 2,071 | $378K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 3,493 | $349K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 1,070 | $330K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.3% | 1,039 | $240K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.2% | 466 | $221K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.1% | 864 | $208K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,812 | $118K |
| 99285 | Emergency room visit (most serious) | <1% | 549 | $115K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 265 | $114K |
| 80053 | Comprehensive metabolic panel | <1% | 26,572 | $111K |
| G0378 | Hospital observation service, per hour | <1% | 3,121 | $97K |
| 93971 | <1% | 851 | $95K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,053 | $92K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 709 | $69K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 376 | $62K |
| 76830 | Ultrasound, transvaginal | <1% | 838 | $57K |
| 96367 | <1% | 363 | $43K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 743 | $39K |
| 80320 | <1% | 1,513 | $37K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,121 | $36K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 468 | $33K |
| 87631 | <1% | 902 | $33K | |
| 97161 | <1% | 272 | $32K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 225 | $32K |
| 70544 | <1% | 49 | $30K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 28,346 | $29K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,022 | $27K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 518 | $22K |
| 72131 | <1% | 225 | $21K | |
| 71250 | <1% | 242 | $19K | |
| 97804 | <1% | 39 | $18K | |
| 97116 | <1% | 229 | $18K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $17K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 33 | $16K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,491 | $15K |
| 93970 | <1% | 63 | $15K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,442 | $14K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,642 | $14K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 855 | $13K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,127 | $13K |
| 96415 | <1% | 20 | $12K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,187 | $12K |
| 0002A | <1% | 422 | $11K | |
| 0001A | <1% | 378 | $11K | |
| 83880 | <1% | 1,371 | $9K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,082 | $9K |
| 93975 | <1% | 54 | $8K | |
| 97803 | <1% | 41 | $8K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,231 | $8K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 418 | $7K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 749 | $7K |
| 87040 | <1% | 1,449 | $7K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,176 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,419 | $6K |
| 97113 | <1% | 29 | $6K | |
| 84484 | <1% | 6,950 | $6K | |
| 86850 | <1% | 2,412 | $5K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 27 | $5K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 666 | $4K |
| 85379 | <1% | 893 | $4K | |
| 81001 | <1% | 7,474 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,124 | $3K |
| 87186 | <1% | 767 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,997 | $3K |
| 82962 | <1% | 5,418 | $3K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,032 | $3K |
| 85027 | <1% | 1,529 | $3K | |
| 73030 | <1% | 329 | $3K | |
| 73630 | <1% | 301 | $3K | |
| 73564 | <1% | 594 | $3K | |
| 86900 | <1% | 2,494 | $3K | |
| 83605 | <1% | 2,521 | $3K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 125 | $2K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 47 | $2K |
| 84703 | <1% | 7,007 | $2K | |
| 97162 | <1% | 13 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 977 | $2K |
| 76801 | <1% | 41 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,834 | $2K |
| 36591 | <1% | 19 | $2K | |
| 83735 | <1% | 2,891 | $2K | |
| 86920 | <1% | 13 | $2K | |
| 86901 | <1% | 2,518 | $1K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 870 | $1K |
| 85610 | <1% | 2,958 | $1K | |
| 97165 | <1% | 14 | $1K | |
| 81003 | <1% | 2,581 | $1K | |
| 84439 | <1% | 170 | $956.30 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 97 | $936.02 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 741 | $894.36 |
| 90715 | <1% | 21 | $799.34 | |
| 83690 | <1% | 5,893 | $647.82 | |
| 0012A | <1% | 13 | $576.81 | |
| 84702 | <1% | 525 | $534.85 | |
| J3490 | Unclassified drugs | <1% | 3,287 | $527.65 |
| 70486 | <1% | 13 | $494.68 | |
| 73610 | <1% | 116 | $449.47 | |
| 87077 | <1% | 901 | $432.56 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,731 | $397.63 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 176 | $394.15 |
| 0031A | <1% | 12 | $324.54 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 17 | $286.58 |
| J7070 | Infusion, d5w, 1000 cc | <1% | 1,344 | $261.98 |
| 94799 | <1% | 30 | $233.34 | |
| 85730 | <1% | 1,304 | $219.59 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,009 | $158.01 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,369 | $141.25 |
| 96376 | <1% | 1,507 | $125.54 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,063 | $124.80 |
| 84466 | <1% | 45 | $122.12 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,774 | $107.08 |
| 83540 | <1% | 45 | $100.35 | |
| 86140 | <1% | 104 | $73.60 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,487 | $69.99 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,515 | $54.91 |
| 84100 | <1% | 144 | $54.88 | |
| 82728 | <1% | 15 | $54.50 | |
| 73130 | <1% | 45 | $40.43 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 751 | $38.48 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,736 | $34.30 |
| 87800 | <1% | 12 | $31.92 | |
| 85652 | <1% | 95 | $29.74 | |
| 87070 | <1% | 51 | $28.28 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 917 | $22.87 |
| A9270 | Non-covered item or service | <1% | 15,107 | $20.96 |
| 80061 | Lipid panel | <1% | 30 | $15.21 |
| 82077 | <1% | 403 | $14.72 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,413 | $14.31 |
| 80076 | <1% | 192 | $13.23 | |
| 82550 | <1% | 95 | $11.80 | |
| 81015 | <1% | 63 | $8.98 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 395 | $8.37 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,648 | $6.12 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 752 | $6.06 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 578 | $2.18 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 433 | $1.32 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 506 | $1.20 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 198 | $0.48 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 158 | $0.24 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 16 | $0.24 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 31 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 36 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 21 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 21 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 12 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 87 | $0.00 |
| 87430 | 0% | 33 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 43 | $0.00 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 13 | $0.00 |
| 0637 | 0% | 889 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 75 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 102 | $0.00 |
| G1012 | Clinical decision support mechanism agilemd, as defined by the medicare appropriate use criteria program | 0% | 123 | $0.00 |
| A4649 | Surgical supply; miscellaneous | 0% | 12 | $0.00 |
| 82948 | 0% | 16 | $0.00 | |
| 96417 | 0% | 133 | $0.00 | |
| 81025 | 0% | 13 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 220 | $0.00 |
| 94664 | 0% | 30 | $0.00 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAVIS, RICHARD (PRESIDENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.